[A Phase 1 study of beta-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP)].
[A Phase 1 study of beta-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP)].
复制标题
[β-甲基-p-(123I)-碘苯基-十五烷酸 (123I-BMIPP) 的 1 期研究]。
DOI：
--
复制
发表时间：
1991
影响因子：
--
通讯作者：
M. Hino
中科院分区：
文献类型：
--
作者：
K. Torizuka;Y. Yonekura;T. Nishimura;N. Tamaki;T. Uehara;K. Ikekubo;M. Hino
β-甲基-p-(123I)-碘苯基十五烷酸（123I-BMIPP）是一种用于评估心肌脂肪酸代谢的新型放射性药物，在六名正常志愿者中进行了第一阶段研究，以评估其生物分布和安全性。静脉注射 111 MBq 123I-BMIPP 后，药物迅速积聚至心肌（注射后 1.5 小时为 5.4 +/- 0.6%），并缓慢被冲出（3.0 小时为 5.1 +/- 0.4%）。 123I-BMIPP 没有在心肌、肝脏和肌肉以外的任何特定器官中显着蓄积。注射后 30 分钟和 3 小时获得的平面图像和 SPECT 图像中心肌清晰可见。 MIRD方法估计的123I-BMIPP在所有器官中的吸收剂量均低于201Tl的吸收剂量。安全性评价中未发现不良反应或异常临床实验室检查结果。这些结果表明 123I-BMIPP 是一种有前途的评估心肌脂肪酸代谢的试剂。
Phase 1 study of beta-methyl-p-(123I)-iodophenylpentadecanoic acid (123I-BMIPP), a new radiopharmaceutical developed for the evaluation of myocardial fatty acid metabolism, was performed in six normal volunteers to evaluate its biodistribution and safety. After intravenous injection of 111 MBq of 123I-BMIPP, the agent accumulated to the myocardium rapidly (5.4 +/- 0.6% at 1.5 hr after injection) and was washed-out slowly (5.1 +/- 0.4% at 3.0hr). 123I-BMIPP demonstrated no significant accumulation to any specific organs other than myocardium, liver and muscle. Myocardium was clearly visualized in the planar and SPECT images obtained 30 min and 3 hrs after injection. The absorption doses from 123I-BMIPP estimated by MIRD method were lower than those from 201Tl in all organs. Neither adverse reactions nor abnormal clinical laboratory findings were found in the safety evaluation. These results suggest 123I-BMIPP is a promising agent for evaluating myocardial fatty acid metabolism.